| Metric | Value (₹ Cr) | vs Q4 FY26 |
|---|---|---|
| Revenue | 23.52 | 271.9% |
| Total Income | 24.06 | 230.9% |
| Expenditure | 5.89 | 14.5% |
| PBT | 18.17 | 4662.0% |
| Net Profit | 12.96 | 855.1% |
| OPM | 81.39% | 70.32pp |
| NPM | 53.85% | 77.45pp |
| EPS | 0.30 | 650.0% |
Pharma revenue/PAT growth is real and margin expanded sharply (OPM 24%→81%), but off a tiny ~₹5 Cr base, so the magnitude is discounted from a standout to a solid-but-not-top-tier quarter.
Shukra Pharmaceuticals Lists on NSE, Trading Begins Aug 14
14 Aug 2026 · 14 Aug, 12:00 pm
Summary
Shukra Pharmaceuticals Limited has announced its direct listing on the National Stock Exchange (NSE) of India, with trading commencing on August 14, 2026. This move from the Bombay Stock Exchange (BSE) is intended to enhance visibility, attract more investors, and improve market liquidity. Managing Director Mr. Dakshesh Shah expressed that this listing signifies the company's strong financial health and operational scaling, positioning it closer to becoming a premier name in global pharmaceutical manufacturing. The dual-listing strategy is presented as a way to offer a more accessible platform for new investors while maintaining transparent corporate governance.
Key Highlights
- 1
Shukra Pharmaceuticals Limited announced its equity shares have been approved for listing and regular trading on the Main Board of the National Stock Exchange of India Limited (NSE).
- 2
The company has achieved a landmark milestone with its ceremonial opening bell ringing at the NSE Exchange Plaza, Mumbai, on Friday, 14th August 2026.
- 3
This transition to the NSE represents a direct listing from the Bombay Stock Exchange (BSE), where the company's shares will continue to trade actively.
- 4
The dual-listing strategy is aimed at expanding the company's visibility, attracting a broader base of institutional and retail investors, and deepening market liquidity.
- 5
Mr. Dakshesh Shah, Managing Director, stated that the listing on the NSE marks a major milestone reflecting strong financial health and operational scaling.
- 6
The direct listing on the NSE is highlighted as a testament to the company's transparent corporate governance and the trust of its shareholders on the BSE.
Management Comments
Dakshesh Shah
Our listing on the National Stock Exchange of India marks a major milestone in our corporate Jjourney. This step reflects our strong financial health and operational scaling. By trading on the NSE, we are expanding our reach to institutional investors and increasing market liquidity. This moves us closer to our goal of becoming a premier name in global pharmaceutical manufacturing. We are proud to see Shukra Pharmaceuticals enter India’s premier equity platform. This direct listing is a testament to our transparent corporate governance and the trust of our shareholders on the BSE. As a dual-listed entity, we offer a more accessible platform for new investors. We remain committed to driving sustainable, long-term value for everyone involved.
Informational and educational content only. Not investment advice.